Prof. Riccardo Dolcetti is a clinician scientist with MD specializations in Oncology and Clinical Immunology with >20y experience in translational research. He is currently the Head of Clinical and Translational Immunotherapy at the Peter MacCallum Cancer Centre, Victorian Comprehensive cancer centre and Department of Microbiology and Immunology Oncology, University of Melbourne. The research of his lab is focused on the identification, validation and clinical exploitation of novel antigen-specific and cell-based immunotherapies and the development and clinical application of immune assays to monitor immune responses in cancer patients. He has a documented expertise in the field of infection-driven tumours, breast cancer and brain tumours. He recently co-developed a nanoparticle-based vaccination platform able to selectively deliver various types of antigens to the most potent antigen presenting cells in vivo and generate strong and specific immunity. He successfully administered multi-institutional research programs and projects and published >260 peer-reviewed papers with >10,000 citations. He had the privilege to be elected President of the Italian Society for Cancer Research (2012-13).